| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6596750 | NOVARTIS | Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators |
Jun, 2017
(6 years ago) | |
| US6465504 | NOVARTIS | Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators |
Apr, 2019
(5 years ago) | |
Exjade is owned by Novartis.
Exjade contains Deferasirox.
Exjade has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Exjade are:
- US6596750
- US6465504
Exjade was authorised for market use on 02 November, 2005.
Exjade is available in tablet, for suspension;oral dosage forms.
Exjade can be used as method of treating chronic iron overload.
The generics of Exjade are possible to be released after 23 July, 2023.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-239) | Dec 12, 2021 |
| Orphan Drug Exclusivity(ODE-39) | Jan 23, 2020 |
| M(M-241) | Jul 24, 2022 |
| M(M-263) | Jul 23, 2023 |
| Orphan Drug Exclusivity(ODE) | Nov 02, 2012 |
| New Indication(I-665) | Jan 23, 2016 |
Drugs and Companies using DEFERASIROX ingredient
Market Authorisation Date: 02 November, 2005
Treatment: Method of treating chronic iron overload
Dosage: TABLET, FOR SUSPENSION;ORAL
How can I launch a generic of EXJADE before it's drug patent expiration?
More Information on Dosage
EXJADE family patents
